Baudax Bio Company Description
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings.
The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.
Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Geraldine Henwood |
Contact Details
Address: 490 Lapp Road Malvern, Pennsylvania 19355 United States | |
| Phone | 484 395 2440 |
| Website | baudaxbio.com |
Stock Details
| Ticker Symbol | BXRXQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US07160F4046 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Geraldine A. Henwood Ph.D. | President, Chief Executive Officer and Director |
| Mike Choi | Vice President of Financial Planning and Analysis |
| Natalie McAndrew | Consultant and Principle Accounting Officer |
| Dr. Chan Kim Yong Ph.D. | Chief Scientific Officer and Director |